Was listed for welcome and introduction/opening remarks at the 2025 pulmonary hypertension symposium
As of 2025 · Last known relationship
Terry Ann Fortin is an Associate Professor of Medicine at Duke University. Her documented clinical interests include adult congenital heart disease and secondary pulmonary hypertension associated with congenital heart disease. She has been identified as co-director of Duke University Medical Center’s Pulmonary Vascular Disease Center, with the timing of that role unspecified in the supplied evidence. Her co-authored publications from 2019 through 2025 address pulmonary hypertension therapies, genetic variants, registry characteristics, diagnostic evaluation, and clinical outcomes. Fortin earned her M.D. from the University of Massachusetts, Amherst, in 1999, completed a Duke medical residency from 1999 to 2002, and was a Duke Fellow in Cardiology from 2002 to 2006. She has supervised Duke Cardiac Intensive Care Unit teaching materials and participated in pulmonary hypertension symposium programming.
Each topic is linked to its supporting source in Sources.
Training includes Was listed for welcome and introduction/opening remarks at the 2025 pulmonary hypertension symposium, Was listed to speak on the cost of pulmonary hypertension at the 2023 pulmonary hypertension symposium, Was listed for welcome and opening remarks at the 2023 pulmonary hypertension symposium, and Fellow in Cardiology at Duke University, plus 12 more records.
Explore education and trainingAs of 2025
As of 2023
As of 2023
As of 2006
As of 2002
As of 1999
Co-authored publication evaluating patients with severe pulmonary hypertension prescribed inhaled treprostinil[5]
2024
Co-authored publication on clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension[5]
2019
Co-authored publication on pericardial effusions and sotatercept therapy in pulmonary arterial hypertension[5]
2025
Co-authored publication on planned initiation of venoarterial extracorporeal membrane oxygenation before liver transplantation[5]
2021
Co-authored publication on rare variant analysis of pulmonary arterial hypertension cases[5]
2021
Co-authored publication on the United States Pulmonary Hypertension Scientific Registry baseline characteristics[5]
2021
Co-authored publication on the utility of electrocardiographic findings in acute pulmonary embolism[5]
2023
Co-authored publication on transitioning from parenteral prostacyclins to selexipag in pulmonary arterial hypertension[5]
2020
Co-authored publication on treatment-related biomarkers in pulmonary hypertension patients on oral therapies[5]
2020
Co-authored publication on unexplained dyspnea on exertion[5]
2022